BEAM-302 shows durable efficacy and safety in AATD
BEAM-302 showed durable, one-time correction of AAT biology in AATD patients, achieving protective AAT levels, reducing disease-driving Z-AAT, and maintaining a favorable safety profile. Regulatory alignment supports an accelerated approval pathway.
BEAM-302 demonstrated durable, one-time correction of AAT biology in AATD patients, with protective AAT levels achieved, disease-driving Z-AAT reduced and a favorable safety profile maintained. Regulatory alignment supports an accelerated approval pathway, while pivotal global dosing is ongoing and stro...